SCHEMBL46288

SCHEMBL46288

CCN(CC)CC#Cc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 5/20 0.58
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
CYP2C9 P11712 2/20 0.50
CYP2C19 P33261 2/20 0.50
CYP2D6 P10635 1/20 0.50
NPY2R P49146 1/20 0.50
NPSR1 Q6W5P4 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
THPO P40225 1/20 0.48
PYCR1 P32322 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
KDM4E B2RXH2 1/20 0.47
BLM P54132 1/20 0.47
PMP22 Q01453 1/20 0.47
LMNA P02545 1/20 0.46
HTR2A P28223 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28486049 0.86 KCNH2 (0.61) KCNH2CYP2C9CYP2C19NPSR1CYP1A2
SCHEMBL8136691 0.83 CYP2A6 (0.61) KCNH2MEN1KMT2ACYP2C9CYP2C19
SCHEMBL12203970 0.82 KCNH2 (0.83) KCNH2MEN1KMT2ANPSR1SMN1; SMN2
SCHEMBL2236681 0.80 KCNH2 (0.59) KCNH2MEN1KMT2ACYP2C9CYP2C19
SCHEMBL10803161 0.80 ALDH1A1 (0.54) KCNH2CYP2C9CYP2C19NPSR1CYP1A2
SCHEMBL19420119 0.79 PYCR1 (0.47) KCNH2CYP2C9CYP2C19NPSR1CYP1A2
SCHEMBL13259172 0.78 PYCR1 (0.54) KCNH2CYP2C9CYP2C19CYP1A2CYP3A4
SCHEMBL9784153 0.75 NPSR1 (0.63) MEN1KMT2ACYP2C9CYP2C19NPSR1
SCHEMBL2092478 0.75 NPSR1 (0.63) MEN1KMT2ACYP2C9CYP2C19NPSR1
SCHEMBL19583155 0.73 GRM5 (0.57) MEN1KMT2ACYP2C9CYP2C19NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160052863-A1 PROCESS FOR PRODUCING AN AMINOPROPYNE OR ENAMINONE AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2016-02-25 US disclosed
EP-1719768-B1 NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS ASAHI KASEI PHARMA CORP (JP) 2012-04-25 EP disclosed
US-8124584-B2 Macrocyclic hepatitis C serine protease inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2012-02-28 US disclosed
US-20120015925-A1 NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS ASAHI KASEI PHARMA CORPORATION (JP) 2012-01-19 US disclosed
US-20120015925-A1 NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS ASAHI KASEI PHARMA CORPORATION (JP) 2012-01-19 US disclosed
WO-2012005692-A1 PROPARGYLAMINE SYNTHESIS USING A COPPER (I) CATALYSED THREE COMPONENT COUPLING REACTION AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2012-01-12 WO disclosed
US-7973030-B2 Benzothiazepine and benzothiepine compounds ASAHI KASEI PHARMA CORPORATION (JP) 2011-07-05 US disclosed
US-7973030-B2 Benzothiazepine and benzothiepine compounds ASAHI KASEI PHARMA CORPORATION (JP) 2011-07-05 US disclosed
US-7803792-B2 Quaternary ammonium compounds ASAHI KASEI PHARMA CORPORATION (JP) 2010-09-28 US disclosed
US-7803792-B2 Quaternary ammonium compounds ASAHI KASEI PHARMA CORPORATION (JP) 2010-09-28 US disclosed
US-7312208-B2 Quaternary ammonium compounds ASAHI KASEI PHARMA CORPORATION (JP) 2007-12-25 US disclosed
US-20070203115-A1 Novel quaternary ammonium compounds ASAHI KASEI PHARMA CORPORATION (JP) 2007-08-30 US disclosed
US-20070203115-A1 Novel quaternary ammonium compounds ASAHI KASEI PHARMA CORPORATION (JP) 2007-08-30 US disclosed
US-20070190041-A1 Novel benzothiazepine and bensothiepine compounds ASHAI KASEI PHARAMA CORPORATION (JP) 2007-08-16 US disclosed
US-20070190041-A1 Novel benzothiazepine and bensothiepine compounds ASHAI KASEI PHARAMA CORPORATION (JP) 2007-08-16 US disclosed
EP-1590442-A4 MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS ENANTA PHARM INC (US) 2007-07-18 EP disclosed
EP-1590442-A3 MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS Enanta Pharmaceuticals, Inc. (US) 2005-11-03 EP disclosed
EP-1590442-A2 MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS Enanta Pharmaceuticals, Inc. (US) 2005-11-02 EP disclosed
US-20050153877-A1 Macrocyclic hepatitis C serine protease inhibitors ENANTA PHARMACEUTICALS, INC. 2005-07-14 US disclosed
WO-2004072243-A2 MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS ENANTA PHARMACEUTICALS, INC. (US) 2004-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050153877-A1 Macrocyclic hepatitis C serine protease inhibitors PRSS1, SPINT2, TMPRSS4 KCNH2 4076/4885MEN1 4037/4885KMT2A 2443/4885
US-20070203115-A1 Novel quaternary ammonium compounds SLC10A2, SLC10A1, ABCB11 KCNH2 818/4885MEN1 3457/4885KMT2A 3183/4885
US-20160052863-A1 PROCESS FOR PRODUCING AN AMINOPROPYNE OR ENAMINONE AADAT, AAAS, AADAC KCNH2 1060/4885MEN1 1717/4885KMT2A 514/4885
US-20120015925-A1 NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS SLC10A1, SREBF1, SPTLC1 KCNH2 1289/4885MEN1 3975/4885KMT2A 404/4885
US-20070190041-A1 Novel benzothiazepine and bensothiepine compounds SLC10A1, GOT1, CES1 KCNH2 1355/4885MEN1 3722/4885KMT2A 486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.